NATALIYA HAYES: Open Payments
NPI 1316355266 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 19 payments from 6 companies in 2025. Trend: 2023 $626 · 2024 $1,058 · 2025 $1,493
Food & beverage: $1,493
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $368 |
| Otsuka America Pharmaceutical, Inc. | 6 | $353 |
| Teva Pharmaceuticals USA, Inc. | 3 | $310 |
| E.R. Squibb & Sons, L.L.C. | 3 | $231 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $153 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $77 |
Products named: UZEDY, ARISTADA, ABILIFY MAINTENA, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, LYBALVI.
Industry payments across CO — which companies pay providers there.
